What is Lormetazepam?
Lormetazepam is a short-acting benzodiazepine hypnotic used for the short-term treatment of severe insomnia in adults. It is available under brand names including Noctamid and Loramet in certain European markets. As a prescription-only controlled medicine, it is reserved for cases where insomnia is clinically significant and has not responded to non-pharmacological interventions or less potent treatments.
Benzodiazepines are among the most studied sleep medicines in clinical medicine. They are effective at reducing sleep onset latency and increasing total sleep time, but their use must be carefully managed due to the risk of tolerance, dependence, and withdrawal.
How does Lormetazepam work?
Lormetazepam acts as a positive allosteric modulator of the GABA-A receptor — the primary inhibitory receptor system in the brain. By enhancing the effect of gamma-aminobutyric acid (GABA), lormetazepam increases the frequency of chloride ion channel opening, producing widespread neuronal inhibition. This results in:
- Sedation and hypnosis: Reduced alertness and induction of sleep
- Anxiolysis: Reduction of anxiety
- Muscle relaxation: Reduced muscle tone
- Anticonvulsant effects: Raised seizure threshold
Lormetazepam’s relatively short half-life (approximately 10–12 hours, with active metabolites having shorter durations) makes it more suitable than longer-acting benzodiazepines (such as diazepam) for insomnia, as the risk of significant next-day sedation is comparatively reduced.
Who is Lormetazepam for?
Lormetazepam is indicated for adults with severe insomnia — specifically where the condition is:
- Significantly impacting daytime functioning, occupational performance, or quality of life
- Persistent and has not responded to sleep hygiene measures and other interventions
- Sufficiently severe to warrant a short course of benzodiazepine treatment in the clinical judgement of a doctor
It is not appropriate for mild or moderate sleep difficulties that have not been addressed with non-pharmacological approaches. Clinical guidelines across EU member states consistently recommend cognitive behavioural therapy for insomnia (CBT-I) as the first-line treatment.
Lormetazepam is contraindicated in:
- Adults with sleep apnoea syndrome
- People with myasthenia gravis
- Patients with severe respiratory insufficiency
- Those with severe hepatic impairment
- Patients with a current or prior history of alcohol or drug dependence
- Pregnant or breastfeeding women
Posologia
Lormetazepam is taken orally, typically as a tablet, approximately 30 minutes before bedtime. Dosing is individualised by the prescribing doctor.
| Group | Typical Dose | Notes |
|---|---|---|
| Adults (general) | 0.5–1 mg at bedtime | Start at lowest effective dose |
| Older adults | 0.5 mg at bedtime | Higher sensitivity; lower dose recommended |
| Maximum recommended duration | 2–4 weeks | Including dose tapering period |
Treatment should begin at the lowest effective dose. The prescribing doctor should review treatment regularly and should not prescribe lormetazepam for longer than necessary. Abrupt discontinuation must be avoided.
Effetti collaterali
Effetti collaterali comuni (possono interessare più di 1 persona su 10)
- Drowsiness or sedation (may persist into the next day)
- Impaired coordination (ataxia)
- Impaired memory (anterograde amnesia — difficulty forming new memories after taking the medicine)
- Confusion, particularly in older adults
- Headache
Serious risks requiring attention
- Physical dependence: Develops with regular use; withdrawal symptoms occur on discontinuation
- Rebound insomnia: Sleep may temporarily worsen upon stopping treatment
- Respiratory depression: Risk is elevated in patients with respiratory compromise or when combined with other CNS depressants
- Paradoxical reactions: Increased anxiety, agitation, and aggression have been reported, particularly in older adults
- Complex sleep behaviours: Including sleep-walking, sleep-driving, and other behaviours with no memory of the event (reported with hypnotic medicines as a class)
- Falls and fractures: Particularly in older adults due to muscle relaxation and impaired coordination
Lormetazepam vs alternatives
| Medicine | Class | Dependence Risk | Duration of Action | Rx Required |
|---|---|---|---|---|
| Lormetazepam | Benzodiazepine | Higher | Intermediate-short | Yes |
| Zopiclone | Z-drug (non-BZD) | Moderate | Short | Yes |
| Zolpidem | Z-drug (non-BZD) | Moderate | Short | Yes |
| Melatonin | Hormone | Minimal | Short | Low dose: No |
| Diphenhydramine | Antihistamine | Low | Long | No |
Clinical guidelines generally recommend Z-drugs (zopiclone, zolpidem) or melatonin before benzodiazepines for most cases of insomnia, given broadly comparable efficacy with potentially more favourable safety profiles. The choice between treatments is a clinical decision for a doctor.
How to access sleep treatment online in Europe
Lormetazepam is a prescription-only controlled medicine. It cannot be legally dispensed without a valid prescription from a qualified medical professional.
Prescrivia operates as a technology intermediary, connecting patients with independent EU-registered doctors for online health assessments. We do not prescribe medicines, employ doctors, or dispense medicines directly. If an independent doctor determines that lormetazepam or another sleep medicine is clinically appropriate following a thorough assessment, they may issue a prescription. This prescription is fulfilled by a licensed EU pharmacy partner.
Importante: Prescrivia does not guarantee that a prescription will be issued. All prescribing decisions are made independently by qualified medical professionals based on individual clinical circumstances, including the appropriateness of benzodiazepine therapy.
Informazioni importanti sulla sicurezza
Non assuma Lormetazepam if you have:
- Sleep apnoea syndrome
- Myasthenia gravis
- Severe respiratory insufficiency
- Severe liver disease
- A history of alcohol or drug dependence
Critical interactions: Lormetazepam must not be combined with alcohol, opioids, or other CNS depressants — the combination significantly increases the risk of respiratory depression, which can be fatal. This combination is responsible for a disproportionate share of drug-related fatalities in Europe, per WHO data.
Guida: Do not drive or operate heavy machinery after taking lormetazepam. The sedating effects, combined with anterograde amnesia, render driving dangerous.
Fonti
Le informazioni mediche presenti in questa pagina si basano sulle seguenti fonti:
- European Medicines Agency (EMA). Reflection paper on the use of benzodiazepines and Z-drugs. EMA/CHMP/2014.
- World Health Organization (WHO). Benzodiazepines (WHO Drug Information). who.int
- European Sleep Research Society (ESRS). European Guideline for the Diagnosis and Treatment of Insomnia. J Sleep Res. 2017;26(6):675-700.
Questo contenuto viene rivisto periodicamente per riflettere le linee guida cliniche aggiornate. Viene fornito esclusivamente a scopo informativo e non costituisce consulenza medica. Consulti sempre un professionista sanitario qualificato per consigli pertinenti alle Sue circostanze di salute individuali.
Frequently asked questions
- What is Lormetazepam used for?
- Lormetazepam is a short-acting benzodiazepine prescribed for the short-term treatment of severe insomnia that is significantly impairing quality of life, where other measures have proven insufficient. It è un farmaco soggetto a prescrizione medica in tutti gli stati membri dell'UE.
- How quickly does Lormetazepam work?
- Lormetazepam is rapidly absorbed and typically takes effect within 15 to 30 minutes of oral administration. Its relatively short duration of action (4–6 hours) is designed to help sleep initiation and maintenance while reducing next-day sedation compared to longer-acting benzodiazepines.
- Is Lormetazepam addictive?
- Yes, benzodiazepines including lormetazepam carry a clinically significant risk of physical and psychological dependence. Dependence can develop within a few weeks of regular use. For this reason, lormetazepam is only recommended for short-term use (typically 2–4 weeks maximum) under medical supervision.
- What happens when I stop taking Lormetazepam?
- Stopping lormetazepam abruptly after regular use can cause withdrawal symptoms including rebound insomnia (sleep temporarily worse than before treatment), anxiety, tremor, and in severe cases, seizures. Dose tapering under medical guidance is strongly recommended.
- Who should not take Lormetazepam?
- Lormetazepam is contraindicated in people with myasthenia gravis, severe respiratory insufficiency, sleep apnoea syndrome, severe liver disease, or a history of substance dependence. It must not be combined with alcohol or other CNS depressants.
Trattamenti
Prescrivia è solo una piattaforma di intermediazione. Non forniamo servizi medici, non prescriviamo trattamenti e non dispensiamo farmaci. Tutte le decisioni mediche sono prese da medici indipendenti registrati nell'UE. Tutti i farmaci sono dispensati da farmacie autorizzate dell'UE. Questa piattaforma facilita i collegamenti tra pazienti e operatori sanitari.